PART I . Overview We are a clinical-stage specialty immunotherapy company harnessing one of natures most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patie...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014326 | EDGAR | 89K words |
| 2025-04-02 | 2024-12-31 | 0001641172-25-002426 | EDGAR | — |
| 2024-04-29 | 2023-12-31 | 0001493152-24-016796 | EDGAR | — |
| 2023-04-17 | 2022-12-31 | 0001410578-23-000698 | EDGAR | — |
| 2022-04-01 | 2021-12-31 | 0001410578-22-000810 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-022641 | EDGAR | 28K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024101 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010395 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0001493152-24-046839 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032294 | EDGAR | — |
| 2024-05-28 | 2024-03-31 | 0001493152-24-021650 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040622 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029606 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001410578-23-001349 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003394 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001410578-22-002585 | EDGAR | — |
| 2022-05-17 | 2022-03-31 | 0001410578-22-001755 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001493152-26-012701 | EDGAR | 1K words |
| 2026-03-04 | 0001493152-26-008786 | EDGAR | — |
| 2026-02-25 | 0001493152-26-008065 | EDGAR | — |
| 2026-01-30 | 0001493152-26-004461 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015784 | EDGAR | — |
| 2025-07-10 | 0001641172-25-018533 | EDGAR | — |
| 2025-07-03 | 0001641172-25-017873 | EDGAR | — |
| 2025-06-30 | 0001641172-25-017198 | EDGAR | — |
| 2025-06-23 | 0001641172-25-016126 | EDGAR | — |
| 2025-06-03 | 0001641172-25-013396 | EDGAR | — |
81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001860871 |
| Ticker | TVGN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tevogen.com |
| Listed | 2024-02-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report